ArticleCancers2020
Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group.Current oncology reports · 2022Pooled it
- Multi-omics analysis in suspected hereditary breast and ovarian cancer cases reveals novel candidate susceptibility factors.NPJ breast cancer · 2026Article
- Carrier screening in the reproductive setting-Are there medical implications for the heterozygote?-A guide for clinicians.Pregnancy (Hoboken, N.J.) · 2026Review
- Fanconi anemia complementation group C gene (FANCC) association with hereditary and sporadic renal tumors.The oncologist · 2026Article
- Possible link between the apparently pathogenicFrontiers in genetics · 2026Article
- Reference-free RNA profiling predicts triple negative breast cancer chemoresistance to neoadjuvant treatment.NAR cancer · 2025Article
- PathogenicCurrent issues in molecular biology · 2025Article
- Exome sequencing reveals new insights into the germline landscape of inflammatory breast cancer among Tunisian patients.Journal of translational medicine · 2025Article
- Heterozygous Germline Fanconi Anemia-Related Gene Mutations Increase Susceptibility to Germ Cell Tumors.JCO precision oncology · 2025Article
- Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients.International journal of cancer · 2025Article
- Occult epidermal growth factor receptor-mutant lung adenocarcinoma complicated by prostatic metastasis: a case report.Anti-cancer drugs · 2025Article
- Integrated analysis of FANCE expression and its regulatory role in the immune microenvironment of oral squamous cell carcinoma.Oncology letters · 2025Article
- A Risk Model Developed based on Homologous Recombination Deficiency Genes for Evaluating the Drug Sensitivity and Prognostic Prediction of Lung Adenocarcinoma.Current medicinal chemistry · 2025Article
- DNA phenotyping and mapping intragenic deletion mutations in Fanconi anemia: Patterns and diagnostic inferences.Journal, genetic engineering & biotechnology · 2024Article
- High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia.International journal of molecular sciences · 2024Article
- Article
- An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness.International journal of molecular sciences · 2024Article
- Article
- A comprehensive study evaluating germline FANCG variants in predisposition to breast and ovarian cancer.Cancer medicine · 2024Article
- FANCM Gene Variants in a Male Diagnosed with Sertoli Cell-Only Syndrome and Diffuse Astrocytoma.Genes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Jesús Del ValleHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.ORCID 0000-0003-3607-7045
Paula RofesHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.ORCID 0000-0001-6045-7879
José Marcos Moreno-CabreraHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.ORCID 0000-0001-8570-0345
Adriana López-DórigaOncology Data Analytics Program (ODAP), Catalan Institute of Oncology, 08908 Hospitalet de Llobregat, Spain.
Sami BelhadjHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.ORCID 0000-0002-0528-9187
Gardenia Vargas-ParraHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Àlex TeuléHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Raquel CuestaHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Xavier MuñozHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Olga CamposHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Mónica SalinasHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Rafael de CidGenomes for Life-GCAT lab Group, Institut Germans Trias i Pujol (IGTP), 08916 Badalona, Spain.
Joan BrunetHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Sara GonzálezHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Gabriel CapelláHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.ORCID 0000-0002-4669-7320
Marta PinedaHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.ORCID 0000-0002-5403-5845
Lídia FeliubadalóHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Conxi LázaroHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08908 Hospitalet de Llobregat, Spain.
Institut d'Investigació Biomédica de Bellvitge · ESInstitut Català d'Oncologia · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ES
Funding
Generalitat de Catalunya 2017SGR1282Generalitat de Catalunya 2017SGR496Instituto de Salud Carlos III PI16/01898Instituto de Salud Carlos III PI19/00553
Abstract
Fanconi anemia (FA) is caused by biallelic mutations in FA genes. Monoallelic mutations in five of these genes (
Indexed as
Breast and ovarian cancer riskBreast cancer riskFanconi AnemiaHereditary CancerNGS panel sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.